Reach Us +44-1647-403003
Obesity In Post-menopausal Women Starting Adjuvant Aromatase Inhibitors For Breast Cancer: Is There An Effect Of Body Mass Index On Outcome? | 53455
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Obesity in post-menopausal women starting adjuvant aromatase inhibitors for breast cancer: Is there an effect of body mass index on outcome?

3rd World Congress on Women’s Health & Breast Cancer

Jamal Zekri, Kamel Farag and Ahmed Allithy

AlFaisal University, Saudi Arabia King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956.C1.087

Introduction: Aromatization of androgens accounts for the peripheral formation of significant proportion of estrogen. For this reason, aromatase inhibitors (AIs) including letrzole are standard adjuvant treatments for post-menopausal (PM) women with hormone receptor positive (HR+) breast cancer (BC). Aromatase enzyme activity is predominant in adipose tissue. This has led to speculation that aromatase activity is elevated in obese women and subsequently decreased clinical activity of AIs. In Saudi Arabia, 80% of women with BC are overweight, obese or morbidly obese. Results of international studies investigating the effect of body mass index (BMI) on clinical outcome of women with BC on adjuvant AIs are not conclusive. Certainly, there are no such studies in women from Saudi Arabia. Patients and Methods: The electronic records of consecutive 320 PM women with HR+BC starting adjuvant letrozole between January 2005 and December 2014 were retrospectively reviewed. Individual patients’ data were extracted including: BMI on day of starting letrozole, patients’ and tumors’ characteristics and disease outcome. The co-primary endpoints are (1) Frequency of obesity in this population (2) Comparing relapse free survival (RFS) in non-obese (Group 1: G1; BMI < 30) and obese (Group 2: G2; BMI ≥ 30) patients. Results: One hundred patients (31.25%) were not obese (BMI < 35). Obesity (BMI ≥ 30) and morbid obesity (BMI ≥ 35) are present in 105/320 (32.8%) and 115/320 (35.9%) patients respectively. Known poor prognostic factors including larger tumor size, higher tumor grade and number on involved lymph nodes were associated with shorter RFS (Log Rank; P=0.004, 0.037 and <0.0001 respectively). RFS at 5 years (G1: 75% vs. G2: 90%) and at 8 years (G1: 69% vs. G2: 87%). Median RFS was not reached in both groups (Log Rank; P=0.097). Conclusion: About two thirds of PM women starting adjuvant AIs for BC are classified as obese. In this cohort, obesity did not adversely affect benefit from adjuvant letrozole. Larger cohort is needed to confirm this result.

Jamal Zekri has received his higher medical oncology training in Weston Park Hospital (Sheffield, England). He practiced as a consultant medical oncologist at Clatterbridge Centre for Oncology (Merseyside, England) until April 2008. Currently, he is an associate professor at Al Faisal University and the head of medical oncology services at King Faisal Specialist Hospital & Research Centre (Jeddah, Saudi Arabia). He has published more than 50 papers in peer reviewed journals and presented more than 30 abstracts in international conferences.

Email: [email protected]

Relevant Topics